Abstract
SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen Ã
Original language | English (US) |
---|---|
Pages (from-to) | 1099-1104 |
Number of pages | 6 |
Journal | Cancer Research |
Volume | 51 |
Issue number | 4 |
State | Published - Feb 1991 |
ASJC Scopus subject areas
- Oncology
- Cancer Research